Tirzepatide is covered by Medicaid for type 2 diabetes in all states, but coverage for weight loss is a different story. Federal rules require state Medicaid programs to cover nearly all FDA-approved drugs for their approved uses, and since tirzepatide (sold as Mounjaro) has been approved for type 2 diabetes since 2022, every state must include it. The weight management version (sold as Zepbound) falls into a gray area where states can choose whether to cover it, and most either don’t or impose strict limits.
Coverage for Type 2 Diabetes
Under the Medicaid Drug Rebate Program, states are required to cover drugs approved for diabetes treatment. Mounjaro, the diabetes-branded version of tirzepatide, qualifies. This means if your doctor prescribes tirzepatide specifically for type 2 diabetes, your state Medicaid program must make it available.
That said, “available” doesn’t always mean easy to get. Many states place tirzepatide on their non-preferred drug list for diabetes, which means you’ll likely need to try other medications first. North Carolina, for example, lists Mounjaro as non-preferred among injectable diabetes drugs and requires you to try and fail two preferred alternatives before approval. Other states may have similar step-therapy requirements or prior authorization processes that add time before you can fill the prescription.
Your prescriber will need to submit a diagnosis code confirming type 2 diabetes with the prescription. If tirzepatide is being used purely for weight loss without a diabetes diagnosis, it won’t be covered under the diabetes indication.
Coverage for Weight Loss
This is where things get much harder. Coverage of drugs approved specifically for obesity treatment is optional for state Medicaid programs, and CMS has confirmed that Medicaid generally does not cover these drugs for the weight loss indication. Zepbound, the weight management version of tirzepatide, faces significant access barriers across the country.
Some states that had begun covering GLP-1 medications for weight loss have since pulled back. California’s Medi-Cal program, for instance, ended coverage of Zepbound for weight loss as of January 1, 2026. Previously approved prescriptions were not renewed. The same change applied to other weight loss medications like Wegovy and Saxenda. California still covers Zepbound for obstructive sleep apnea if a prior authorization is submitted, and Mounjaro remains covered for type 2 diabetes with proper diagnosis coding.
A federal initiative called the BALANCE model was designed to expand access to these medications through voluntary agreements between CMS, drug manufacturers, and state Medicaid agencies. But participation is optional on all sides, and the program does not guarantee coverage for any individual patient.
Coverage for Sleep Apnea
Zepbound received FDA approval for moderate-to-severe obstructive sleep apnea, and some states have begun covering it for that specific use. Louisiana’s Medicaid program, for example, covers Zepbound for sleep apnea but applies detailed approval criteria: you must be 18 or older, have a BMI of 30 or above, have a confirmed sleep apnea diagnosis with a recent sleep study, and not have type 1 or type 2 diabetes. You’re also expected to be using or have attempted positive airway pressure therapy, and your prescriber must confirm you’re receiving lifestyle counseling alongside the medication.
These requirements illustrate how narrow the approved pathway can be even in states that do offer coverage beyond diabetes.
How Your Plan Type Affects Access
Medicaid benefits are delivered through two main systems: fee-for-service, where the state pays providers directly for each service, and managed care, where the state contracts with private health plans that receive a fixed monthly payment per enrollee. Most Medicaid beneficiaries are in managed care plans, and these plans sometimes handle prescription drug coverage differently than the state’s fee-for-service program.
Some states carve prescription drugs out of their managed care contracts entirely, meaning the state manages drug coverage separately. Others include drugs within the managed care plan’s responsibilities. If your state uses managed care for pharmacy benefits, your plan may have its own preferred drug list and prior authorization rules that differ from the state’s fee-for-service formulary. This means two Medicaid beneficiaries in the same state could face different coverage requirements depending on which plan they’re enrolled in.
What You’ll Pay Out of Pocket
Medicaid cost-sharing is capped at low levels compared to commercial insurance. For preferred drugs, the maximum copay is $4. For non-preferred drugs, it’s $8 for beneficiaries at or below 150% of the federal poverty level. Those with incomes above 150% of the poverty level may pay up to 20% of what Medicaid pays for non-preferred medications. Since tirzepatide often lands on non-preferred lists, you’re more likely to face the higher copay tier, but even that remains far below the retail price of the drug.
Coverage for Children and Adolescents
Federal rules provide broader protections for Medicaid beneficiaries under 21 through the Early and Periodic Screening, Diagnostic, and Treatment benefit, known as EPSDT. This requirement means states must cover medically necessary treatments for children even when those same treatments are optional for adults. California’s policy explicitly notes that members younger than 21 who need a GLP-1 drug for weight loss can still receive coverage if their prescriber submits a prior authorization request and it’s approved. This is a meaningful distinction, since the same coverage was eliminated for adults in that state.
How to Check Your State’s Coverage
Because Medicaid is administered state by state, the only reliable way to confirm your coverage is to check with your specific program. Start with your state Medicaid agency’s preferred drug list, which is typically published online and updated quarterly. Look for tirzepatide under both injectable diabetes medications and weight management agents. If it’s listed as non-preferred, check the clinical criteria document for step-therapy and prior authorization requirements.
If you’re in a managed care plan, call the number on your Medicaid card and ask the plan’s pharmacy department directly whether tirzepatide is covered for your diagnosis and what steps are needed for approval. Your prescriber’s office can also submit a prior authorization on your behalf and will generally know which documentation the state or plan requires.